Gastrointestinal Cancer. Malignant neoplasm: Ill-defined sites within the digestive system
Conditions
Interventions
Intervention 1: In the treatment group administration of Spinal-Z to the treatment group in addition to the standard treatment. Intervention 2: In the control group administration of the placebo in ad
Treatment - Drugs
Placebo
In the treatment group administration of Spinal-Z to the treatment group in addition to the standard treatment.
In the control group administration of the placebo in addition of standard treatments
Sponsors
Baqiyatallah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
25 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patient with age of 25-75 year-old; Patients with gastric adenocarcinoma or Esophageal squamous cell carcinoma with standard treatment during the study; No sign of metastasis in the patients. Exclusion criteria: Participate in the study with use of any other drugs; history of bone marrow or stem cells transplants; Comorbidities include active infection, respiratory failure, heart failure or left ventricular EF <50%, inflammatory disorders, including rheumatoid arthritis and gout false, thyroid disorders or a history of thyroid antibodies, hyperviscosity syndrome, osteoporosis, anemia, bone marrow disorders such as sickle cell form, thalassemia or myelodysplastic syndrome, immune deficiency and psychiatric diseases that decreases the patient's tolerance; Pregnancy or lactation; Serum creatinine more than 1.5 times the maximum amount of the normal range; AST and ALT more than 1.5 times the upper limit of normal; Alkaline phosphatase greater than 2.5 times the upper limit of the normal range; Bilirubin more than 1.5 mg/dl.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Type of cancer. Timepoint: Before and after of intervention. Method of measurement: Examination and Diagnostic procedures.;Length of the cancer. Timepoint: During the study. Method of measurement: Examination and Diagnostic procedures. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pathology. Timepoint: Before and after of intervention. Method of measurement: Laboratory.;Drug Adverse effects. Timepoint: During the study. Method of measurement: History and physical examination.;Quality of life. Timepoint: Before and after of intervention. Method of measurement: Questionnaire.;Gastrointestinal signs: Abdominal pain, Heart burn, Constipation and vomiting. Timepoint: Before and after of intervention. Method of measurement: History and physical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Yunes Panahi
Baqiyatallah University of Medical Sciences
Outcome results
None listed